Denali Therapeutics (DNLI) Operating Expenses (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Operating Expenses data on file, last reported at $137.4 million in Q1 2026.

• On a quarterly basis, Operating Expenses fell 5.65% year-over-year to $137.4 million in Q1 2026; TTM through Mar 2026 was $547.1 million, a 6.19% increase from a year earlier, with the FY2025 full-year figure at $555.3 million, up 10.65% from the prior year.
• Operating Expenses for Q1 2026 stood at $137.4 million, roughly flat from $137.4 million in the prior quarter.
• Over the last five years, Operating Expenses for DNLI reached as high as $156.0 million in Q1 2023 and fell as low as $108.6 million in Q1 2022.
• Historically, Operating Expenses has averaged $127.7 million across 5 years, with a median of $129.8 million in 2024.
• Across the five-year window, Operating Expenses soared 43.55% in 2023 and fell 15.2% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $115.6 million in 2022, then increased by 14.65% to $132.6 million in 2023, then slipped by 2.06% to $129.8 million in 2024, then increased by 5.79% to $137.4 million in 2025, then retreated by 0.01% to $137.4 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $137.4 million in Q1 2026, $137.4 million in Q4 2025, and $137.4 million in Q3 2025.